Regulatory update: fluticasone furoate/vilanterol submission in Japan

GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the licence application for the use of fluticasone furoate (FF) and vilanterol (VI) (proposed brand name RELVARTM ELLIPTATM) in patients with chronic obstructive pulmonary disease (COPD) has been withdrawn from the current Japanese New Drug Application (JNDA)
Source: GSK news - Category: Pharmaceuticals Source Type: news